those treated with placebo (6.7%), although this difference did not reach statistical significance. 32 Compared to ibandronate, treatment with zoledronate is associated with a 1.5‐fold relative risk of renal impairment despite a better baseline kidney function in a retrospective study including 333 cancer patients. 33 For osteoporosis, zoledronate has been investigated in 4 trials.
1
—
—